Esophageal CancerMAGECmultiDiCENCT06346080
Molecular Analysis for Gastro-Esophageal Cancer: Multicenter Discrete Choice Experiment
A study testing Survey in people with Esophageal Cancer and Gastric Cancer, run by KU Leuven at 1 site in Belgium.
Trial summary
The goal of this survey is to investigate the participants' preference for a specific screening/diagnostic tool to detect and assess gastro-esophageal cancer. The main question it aims to answer are: Which diagnostic modality is preferred by patients and the general population? Which features of the diagnostic test… Read more about this study
- Who is it for?
- Ages 18 to 85 yearsHealthy volunteers can take part
- Conditions the study is for
- Esophageal Cancer, Gastric Cancer
- What is being tested?
- Survey
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 2,200 participants
- Where
- 1 siteBelgium
- Study dates
- 1 Aug 2024to 1 Aug 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Individuals >18yo to 75yo (upper age limit of Barrett's surveillance)
- Access to computer or smartphone
- Clear understanding of available languages of the experiment (English, French, Dutch, Spanish, German, Chinese, Japanese)
Who cannot join
- Individuals less than 18yo and more than 75yo
- Incarcerated individuals
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Belgium1 site, 1 recruiting
- Recruiting
University Hospitals Leuven
Leuven, 3000
Stijn Vanstraelen, MD, 16347863 ext. 0032, stijn.vanstraelen@kuleuven.be
About this study
The goal of this survey is to investigate the participants' preference for a specific screening/diagnostic tool to detect and assess gastro-esophageal cancer.
The main question it aims to answer are:
- Which diagnostic modality is preferred by patients and the general population?
- Which features of the diagnostic test are most detrimental in the decision-making for one or the other modality?
- Are geographical differences present in regard to the preference for a diagnostic modality?
Participants will be asked to complete a survey of 20-25min, including a brief intake regarding their socio-economic status. This approach will allow us to correct for confounding factors.
- Conditions
- Esophageal Cancer, Gastric Cancer
- Being tested
- Survey
- Keywords
- Esophageal cancer, Survey, Gastric cancer
- Medical subject headings
- Esophageal Neoplasms, Stomach Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SurveyOther
Discrete choice survey
| Study group | Role | What they receive |
|---|---|---|
| Survey participants | Experimental | Participants who will complete a survey investigating their preference for diagnosis and assessment of gastro-esophageal cancer Receives: Other: Survey |
What is being measured
The primary outcome is the main question the study is designed to answer.
The rate of contribution of diagnostic features to the preference of participants
A part-worth analysis, expressed as percentage, from a discrete choice experiment (questionnaire) will assess the features that are most important to the participants
Measured: 2 years
The percentage differences in preference of participants between geographical regions
Differences in preferences will be compared between different geographical regions using chi-squared or McNemar's test
Measured: 2 years
Secondary outcomes (2)
Assess the rate patient-level demographics influence the importance of a test feature, expressed as an odds ratio
Assess the influence of demographic characteristics on the decision-making process using a multivariable logistic regression model, providing odds ratios.
Measured: 2 years
Assess the rate of trade-off demonstrated as odds ratio between cancer-related mortality reduction and costs
Based on an anticipated cancer detection and cost, we will assess the willingness-to-pay using a multivariable logistic regression, providing odds ratios.
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Apr 2024
- Study start1 Aug 2024
- Primary completion1 Aug 2026 (estimated)
- Study completion1 Aug 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Esophageal CancerStudies of the same condition, open and under way.
- More trials run by KU LeuvenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- A survey will be conducted in a single group of participants from different geographical regions and backgrounds
- Masking
- None (open label)
- Enrolment
- 2,200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- KU Leuven
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Stijn Vanstraelen, KU Leuven
- Investigators
- Stijn Vanstraelen, MD, Principal investigator, UZ LeuvenPhilippe Nafteux, MD, PhD, Principal investigator, UZ Leuven
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06346080
- Sponsor's protocol ID
- s68670
- Acronym
- MAGECmultiDiCE
- Status last verified
- Feb 2026
- First submitted
- 23 Mar 2024
- Last updated
- 18 Feb 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Data will be made available upon reasonable request with the principal investigator
Study at a glance
From the registry record, last updated by the sponsor on 18 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Molecular Analysis for Gastro-Esophageal Cancer: Multicenter Discrete Choice Experiment
- ClinicalTrials.gov ID
- NCT06346080
- Acronym / sponsor ID
- MAGECmultiDiCE / s68670
- Conditions
- Esophageal Cancer, Gastric Cancer
- Keywords
- Esophageal cancer, Survey, Gastric cancer
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 2,200 participants (estimated)
- Lead sponsor
- KU LeuvenUniversity, hospital or other
- Study start
- 1 Aug 2024 (actual)
- Primary completion
- 1 Aug 2026 (estimated)
- Study completion
- 1 Aug 2026 (estimated)
- First posted
- 3 Apr 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this survey is to investigate the participants' preference for a specific screening/diagnostic tool to detect and assess gastro-esophageal cancer.
The main question it aims to answer are:
- Which diagnostic modality is preferred by patients and the general population?
- Which features of the diagnostic test are most detrimental in the decision-making for one or the other modality?
- Are geographical differences present in regard to the preference for a diagnostic modality?
Participants will be asked to complete a survey of 20-25min, including a brief intake regarding their socio-economic status. This approach will allow us to correct for confounding factors.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- A survey will be conducted in a single group of participants from different geographical regions and backgrounds
| Arm | Type | Receives |
|---|---|---|
| Survey participants | Experimental | Other: SurveyParticipants who will complete a survey investigating their preference for diagnosis and assessment of gastro-esophageal cancer |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Individuals >18yo to 75yo (upper age limit of Barrett's surveillance)
- Access to computer or smartphone
- Clear understanding of available languages of the experiment (English, French, Dutch, Spanish, German, Chinese, Japanese)
Key exclusion criteria (2 listed)
- Individuals less than 18yo and more than 75yo
- Incarcerated individuals
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SurveyDiscrete choice survey | Other | Survey participants |
Primary outcome
The rate of contribution of diagnostic features to the preference of participants
Time frame: 2 years
A part-worth analysis, expressed as percentage, from a discrete choice experiment (questionnaire) will assess the features that are most important to the participants
The percentage differences in preference of participants between geographical regions
Time frame: 2 years
Differences in preferences will be compared between different geographical regions using chi-squared or McNemar's test
2 secondary outcomes
Assess the rate patient-level demographics influence the importance of a test feature, expressed as an odds ratio
Time frame: 2 years
Assess the rate of trade-off demonstrated as odds ratio between cancer-related mortality reduction and costs
Time frame: 2 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Feb 2026.
- Individual participant dataSharing planned: Yes. Data will be made available upon reasonable request with the principal investigator
Related trials for Esophageal Cancer
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
RecruitingObservational study
Multicenter Prospective Cohort on Esophageal Endoscopic Submucosal Dissection
Superficial Esophageal Cancer, Oesophageal Adenocarcinoma
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
RecruitingPhase 1
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Advanced/Metastatic Solid Tumors, Bladder Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Stijn Vanstraelen, MD principal investigator
UZ Leuven
Philippe Nafteux, MD, PhD principal investigator
UZ Leuven
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Survey in people with Esophageal Cancer and Gastric Cancer, run by KU Leuven at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 18 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Stijn Vanstraelen, MD (16346822 ext. 0032, stijn.vanstraelen@kuleuven.be), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The rate of contribution of diagnostic features to the preference of participants (time frame: 2 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Feb 2026.